Torasemide

Torasemide
Clinical data
AHFS/Drugs.com International Drug Names
MedlinePlus a601212
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Oral, IV
ATC code C03CA04 (WHO)
Legal status
Legal status
Pharmacokinetic data
Bioavailability 80-90%
Protein binding Highly bound (>99%).
Metabolism Hepatic (80%)
Biological half-life 3.5 hours; Cirrhosis: 7-8 hours
Identifiers
CAS Number 56211-40-6 YesY
PubChem (CID) 41781
IUPHAR/BPS 7312
DrugBank DB00214 YesY
ChemSpider 38123 YesY
UNII W31X2H97FB YesY
KEGG D00382 YesY
ChEBI CHEBI:9637 N
ChEMBL CHEMBL1148 YesY
ECHA InfoCard 100.164.924
Chemical and physical data
Formula C16H20N4O3S
Molar mass 348.421 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Torasemide (rINN) or torsemide (USAN) is a pyridine-sulfonyl urea type loop diuretic mainly used in the management of edema associated with congestive heart failure. It is also used at low doses for the management of hypertension. It is marketed under the brand names Demadex, Diuver, and Examide.

Compared with other loop diuretics, torasemide has a more prolonged diuretic effect than equipotent doses of furosemide and relatively decreased potassium loss. No evidence of torasemide-induced ototoxicity has been demonstrated in humans.[1]

Recent publications suggest improved outcomes when used for heart failure compared with furosemide.[2][3][4]

References

  1. Dunn CJ, Fitton A, Brogden RN (January 1995). "Torasemide. An update of its pharmacological properties and therapeutic efficacy". Drugs. 49 (1): 121–42. doi:10.2165/00003495-199549010-00009. PMID 7705212.
  2. Roush GC, Kaur R, Ernst ME (2014). "Diuretics: a review and update". J. Cardiovasc. Pharmacol. Ther. 19: 5–13. doi:10.1177/1074248413497257. PMID 24243991.
  3. Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, O'Connor CM (2015). "A reappraisal of loop diuretic choice in heart failure patients". Am. Heart J. 169: 323–33. doi:10.1016/j.ahj.2014.12.009. PMC 4346710Freely accessible. PMID 25728721.
  4. Mentz RJ, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, Ezekowitz JA, Tang WH, Schulte PJ, Anstrom KJ, Hernandez AF, Velazquez EJ, O'Connor CM (2016). "Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial)". Am. J. Cardiol. 117: 404–11. doi:10.1016/j.amjcard.2015.10.059. PMID 26704029.
This article is issued from Wikipedia - version of the 7/30/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.